GeoVax Labs Dirección

Dirección controles de criterios 4/4

El CEO de GeoVax Labs' es David Dodd , nombrado en Sep 2018, tiene una permanencia de 5.58 años. compensación anual total es $384.20K, compuesta por 96.6% salario y 3.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.81% de las acciones de la empresa, por valor de €26.28K. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 14.1 años, respectivamente.

Información clave

David Dodd

Chief Executive Officer (CEO)

US$384.2k

Compensación total

Porcentaje del salario del CEO	96.6%
Permanencia del CEO	5.6yrs
Participación del CEO	0.8%
Permanencia media de la dirección	3yrs
Promedio de permanencia en la Junta Directiva	14.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Dodd en comparación con los beneficios de GeoVax Labs?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$384k	US$371k	-US$26m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$652k	US$309k	-US$14m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$677k	US$250k	-US$19m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$727k	US$250k	-US$3m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$251k	US$250k	-US$2m
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$353k	US$83k	-US$3m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$48k	n/a	-US$2m

Compensación vs. Mercado: La compensación total ($USD384.20K) de David está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de David ha sido consistente con los resultados de la empresa en el último año.

CEO

David Dodd (73 yo)

5.6yrs

Permanencia

US$384,200

Compensación

Mr. David Alan Dodd has been the Chief Executive Officer and President of Geovax Labs, Inc. since September 5, 2018 and has been its Chairman since January 01, 2011 and Director since March 17, 2010. His e...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Dodd	Chairman	5.6yrs	US$384.20k	0.81% $ 24.7k
Mark Newman	Chief Scientific Officer	3.7yrs	US$291.50k	0% $ 0
Kelly McKee	Chief Medical Officer	2.3yrs	US$361.03k	0.10% $ 3.2k
Harriet Robinson	Founder	no data	sin datos	sin datos
Mark Reynolds	CFO & Corporate Secretary	17.5yrs	US$421.40k	0.31% $ 9.6k
Thomas O'Brien	Vice President of Quality Systems & Compliance	no data	sin datos	sin datos
Jeffrey Welch	Head of Process Development & Manufacturing Operations	2.1yrs	sin datos	sin datos
John Niles	Head of Commercial Operations	no data	sin datos	sin datos
John Sharkey	Vice President of Business Development	1.8yrs	sin datos	sin datos

3.0yrs

Permanencia media

70yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de E8LA se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Dodd	Chairman	14.1yrs	US$384.20k	0.81% $ 24.7k
Harriet Robinson	Founder	no data	sin datos	sin datos
Randal Chase	Independent Director	9.1yrs	US$47.50k	0.11% $ 3.2k
John Spencer	Independent Director	17.6yrs	US$45.00k	0.061% $ 1.9k
Robert McNally	Independent Director	17.3yrs	US$47.50k	0.16% $ 4.8k
Stanley Plotkin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Dean Kollintzas	Independent Director	17.6yrs	US$37.50k	0.035% $ 1.1k
Barney Graham	Member of Scientific Advisory Board	no data	sin datos	sin datos
Scott Weaver	Member of Scientific Advisory Board	no data	sin datos	sin datos
Olivera Finn	Member of Scientific Advisory Board	no data	sin datos	sin datos
Nicole Lemerond	Independent Director	1.7yrs	US$32.50k	0% $ 0
Jayne Morgan	Independent Director	1.3yrs	US$30.00k	0% $ 0

14.1yrs

Permanencia media

73yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de E8LA son experimentados ( 14.1 años antigüedad media).

GeoVax Labs Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

High number of new directors

Recent updates

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement

Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster

GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

New major risk - Market cap size

GeoVax Labs Receives a Notice from the Nasdaq Stock Market

Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02

New major risk - Revenue and earnings growth

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

New major risk - Financial position

GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

GeoVax Labs, Inc. Announces Next-Generation COVID-19 Vaccine Data to Be Presented At Two Upcoming Scientific Meetings

Full year 2022 earnings released: US$0.83 loss per share (vs US$3.04 loss in FY 2021)

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs Receives Non-Compliance Notice From Nasdaq

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

High number of new directors

GeoVax Labs, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Geovax Announces Appointment of Nicole Lemerond to Its Board of Directors

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

GeoVax Labs, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GeoVax Labs, Inc., Annual General Meeting, Aug 03, 2022

First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.29 loss in 1Q 2021)

Insufficient new directors

GeoVax Labs, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Geovax Labs, Inc. Announces Management Appointments

GeoVax Labs, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022

GeoVax Labs, Inc. announced that it has received $9.999998 million in funding

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial for Covid-19 Vaccine Booster

GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunotherapy Congress

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.73 loss in 3Q 2020)

Geovax Presents Covid-19 Vaccine Data At the European Society of Medicine (Esmed) General Assembly

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.66 loss in 2Q 2020)

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

First quarter 2021 earnings released: US$0.29 loss per share (vs US$2.54 loss in 1Q 2020)

Full year 2020 earnings released: US$2.14 loss per share

GeoVax Labs, Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

GeoVax Expands and Strengthens Intellectual Property Portfolio

New 90-day high: €5.20

New 90-day high: €4.68

GeoVax Announces License Agreement With NIH to Support Continued Advancements in Vaccine Development

GeoVax Labs, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Geovax Labs, Inc. Announces Signing of Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases

GeoVax Labs Deleted from Other OTC

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad